Endoscopic improvement (dichotomous) · patients with induction of remission in ulcerative colitis
It is very uncertain whether LMWH + standard therapy changes endoscopic improvement compared with standard therapy (very low certainty).
1 finding from 1 review
Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy showed no clear difference in any adverse events compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
QoL · advanced gastric and oesophago‐gastric junction adenocarcinoma
1 finding from 1 review
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Progression‐free survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy probably leads to lower progression‐free survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review
Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy showed no clear difference in serious adverse events compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy may leads to higher tumour response rate compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review
Overall survival · advanced pancreatic cancer
Anti‐cancer therapy showed no clear difference in overall survival compared with best supportive care (moderate certainty).
1 finding from 1 review
Clinical remission or improvement · people with irritable bowel syndrome
It is very uncertain whether biofeedback plus standard therapy changes clinical response (adequate improvement or remission) compared with standard therapy (very low certainty).
1 finding from 1 review
Abdominal pain · people with irritable bowel syndrome
1 finding from 1 review
QoL · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (AE) · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Abdominal pain · people with irritable bowel syndrome
1 finding from 1 review
Clinical remission or improvement · people with irritable bowel syndrome
It is very uncertain whether biofeedback plus standard therapy changes clinical response (adequate improvement or remission) compared with sham biofeedback plus standard therapy (very low certainty).
1 finding from 1 review
QoL · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (AE) · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality ‐ not reported · patients with oesophageal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
TCM symptoms ‐ ineffectiveness · patients with oesophageal cancer
It is very uncertain whether active cancer therapy combined with TCM changes TCM symptoms ‐ ineffectiveness compared with active cancer therapy (very low certainty).
1 finding from 1 review